| 國立成功大學 |
2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
|
Chiu, Chiu C.-H.;Lin, M.-C.;Wei, Y.-F.;Chang, G.-C.;Su, W.-C.;Hsia, T.-C.;Su, J.;Wang, A.K.-F.;Jen, M.-H.;Puri, T.;Shih, J.-Y. |
| 國立成功大學 |
2023 |
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
|
Yang, J.C.-H.;Su, W.-C.;Chiu, Chiu C.-H.;Shiah, H.-S.;Lee, K.-Y.;Hsia, T.-C.;Uno, M.;Crawford, N.;Terakawa, H.;Chen, W.-C.;Takayama, G.;Hsu, C.;Hong, Y.;Saintilien, C.;McGill, J.;Chang, G.-C. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
CHIH-HSIN YANG; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. |
| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; CHIH-HSIN YANG; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-06-27T07:07:55Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU; Chang W.-C.; Kuo H.-P.; Yu C.-T.; Lin Z.-Z.; Kao W.-Y. |
| 臺大學術典藏 |
2022-06-27T07:07:39Z |
Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study
|
Fan W.-C.; CHONG-JEN YU; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T07:06:32Z |
Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan
|
Perng R.-P.; Chen C.-Y.; Chang G.-C.; Hsia T.-C.; Hsu N.-Y.; Tsai Y.-H.; Tsai C.-M.; Yang C.-H.; Chen Y.-M.; CHONG-JEN YU; Lee J.-J.; Hsu H.-S.; Yu C.-T.; Kao E.-L.; Chiu C.-H. |
| 臺大學術典藏 |
2022-06-27T07:02:08Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. |
| 臺大學術典藏 |
2022-06-27T07:01:39Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; CHONG-JEN YU; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:29Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; CHONG-JEN YU; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:17Z |
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
|
Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; Yu S.-L.; Su K.-Y.; CHONG-JEN YU; Ho C.C.; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Yang P.-C.; Chen J.J.W.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:12Z |
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study
|
Chang G.-C.; Tseng C.-H.; Hsu K.-H.; CHONG-JEN YU; Yang C.-T.; Chen K.-C.; Yang T.-Y.; Tseng J.-S.; Liu C.-Y.; Liao W.-Y.; Hsia T.-C.; Tu C.-Y.; Lin M.-C.; Tsai Y.-H.; Hsieh M.-J.; Wu W.-S.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T06:59:40Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2022-06-27T02:49:09Z |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su P.-L.; Chang G.-C.; Hsiao S.-H.; Hsia T.-C.; Lin M.-C.; Lin M.-H.; JIN-YUAN SHIH; Yang C.-T.; Yang S.-H.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T02:49:08Z |
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
|
Popat S.; Hsia T.-C.; Hung J.-Y.; Jung H.A.; JIN-YUAN SHIH; Park C.K.; Lee S.H.; Okamoto T.; Ahn H.K.; Lee Y.C.; Sato Y.; Lee S.S.; Mascaux C.; Daoud H.; M?rten A.; Miura S. |
| 臺大學術典藏 |
2022-06-10T06:11:15Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y. |
| 國立成功大學 |
2022 |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su, P.-L.;Chang, G.-C.;Hsiao, S.-H.;Hsia, T.-C.;Lin, M.-C.;Lin, M.-H.;Shih, J.-Y.;Yang, C.-T.;Yang, S.-H.;Chen, Y.-M. |
| 國立成功大學 |
2022 |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu, S.;Wang, Q.;Zhang, G.;Dong, X.;Yang, C.-T.;Song, Y.;Chang, G.-C.;Lu, Y.;Pan, H.;Chiu, Chiu C.-H.;Wang, Z.;Feng, J.;Zhou, J.;Xu, Xu X.;Guo, R.;Chen, J.;Yang, H.;Chen, Y.;Yu, Z.;Shiah, H.-S.;Wang, C.-C.;Yang, N.;Fang, J.;Wang, P.;Wang, K.;Hu, Y.;He, J.;Wang, Z.;Shi, J.;Chen, S.;Wu, Q.;Sun, C.;Li, C.;Wei, H.;Cheng, Y.;Su, W.-C.;Hsia, T.-C.;Cui, J.;Sun, Y.;Ou, S.-H.I.;Zhu, V.W.;Chih-Hsin, Yang J. |
| 臺大學術典藏 |
2021-11-03T05:24:54Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2021-10-04T07:15:40Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 臺大學術典藏 |
2021-08-20T08:00:37Z |
Lung Cancer in Republic of China
|
Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; Yang J.C.-H.; BIN-CHI LIAO; Hsia T.-C.; Chen Y.-M. |
| 臺大學術典藏 |
2021-08-11T03:46:52Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y. |
| 臺大學術典藏 |
2021-05-02T03:49:14Z |
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
|
Wu S.-G.;Chiang C.-L.;Liu C.-Y.;Wang C.-C.;Su P.-L.;Hsia T.-C.;Jin-Yuan Shih;Chang G.-C.; Wu S.-G.; Chiang C.-L.; Liu C.-Y.; Wang C.-C.; Su P.-L.; Hsia T.-C.; JIN-YUAN SHIH; Chang G.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:03Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:02Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
|
Chih-Hsin Yang;Camidge D.R.;Yang C.-T.;Zhou J.;Guo R.;Chiu C.-H.;Chang G.-C.;Shiah H.-S.;Chen Y.;Wang C.-C.;Berz D.;Su W.-C.;Yang N.;Wang Z.;Fang J.;Chen J.;Nikolinakos P.;Lu Y.;Pan H.;Maniam A.;Bazhenova L.;Shirai K.;Jahanzeb M.;Willis M.;Masood N.;Chowhan N.;Hsia T.-C.;Jian H.;Lu S.; CHIH-HSIN YANG; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
|
Wu Y.-L.;Cheng Y.;Zhou J.;Lu S.;Zhang Y.;Zhao J.;Kim D.-W.;Soo R.A.;Kim S.-W.;Pan H.;Chen Y.-M.;Chian C.-F.;Liu X.;Tan D.S.W.;Bruns R.;Straub J.;Johne A.;Scheele J.;Park K.;Chih-Hsin Yang;Liu Z.;Chen X.;Wang M.;Yu S.;Zhang H.;Fang J.;Li W.;Yang C.-H.;Chang G.-C.;Hsia T.-C.;Yang C.-T.;Wang C.-C.;Cho B.C.;Lee K.H.;Kim Y.-C.;An H.J.;Woo I.S.;Cho J.Y.;Shin S.W.;Lee J.-S.;Kim J.-H.;Yoo S.S.;Kato T.;Shinagawa N.;Tan S.W.D.;Ngo L.S.-M.;Ratnavelu K.;Ahmad A.R.;Liam C.K.;De Marinis F.;Tassone P.;Molla A.I.;Calles Blanco A.;Lazaro Quintela M.E.;Felip Font E.;Dingemans A.-M.;Bui L.; Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. |
| 臺大學術典藏 |
2021-04-23T05:56:24Z |
Lung Cancer in Republic of China
|
Luo Y.-H.;Chiu C.-H.;Scott Kuo C.-H.;Chou T.-Y.;Yeh Y.-C.;Hsu H.-S.;Yen S.-H.;Wu Y.-H.;Chih-Hsin Yang;Liao B.-C.;Hsia T.-C.;Chen Y.-M.; Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; CHIH-HSIN YANG; Liao B.-C.; Hsia T.-C.; Chen Y.-M. |
| 臺大學術典藏 |
2021-03-11T08:34:19Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.;Huang W.-T.;Liu T.-C.;Shieh J.-M.;Chian C.-F.;Wu M.-F.;Chang C.-C.;Lin C.-H.;Jen-Chang Ko;Lin C.-M.;Hsia T.-C.; Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 臺大學術典藏 |
2021-03-11T08:29:33Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 臺大學術典藏 |
2021-03-11T07:58:28Z |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
|
Wei Y.-F.; Huang W.-T.; Liu T.-C.; Shieh J.-M.; Chian C.-F.; Wu M.-F.; Chang C.-C.; Lin C.-H.; JEN-CHANG KO; Lin C.-M.; Hsia T.-C. |
| 國立成功大學 |
2021 |
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study
|
Huang, Y.-H.;Hung, J.-Y.;Ko, H.-W.;Su, P.-L.;Lai, C.-L.;Chang, H.-C.;Hsia, T.-C.;Lin, S.-H.;Wu, K.-L.;Yang, C.-T.;Su, W.-C.;Chu, Y.-C.;Wang, C.-C.;Liao, W.-Y.;Lin, Y.-T.;Lin, C.-H.;Lin, M.-C.;Hsu, K.-H.;Tseng, J.-S.;Yang, T.-Y.;Chen, K.-C.;Lee, M.-H.;Yu, S.-L.;Ho, C.-C.;Chang, G.-C. |
| 國立成功大學 |
2021 |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
Yang, J.C.-H.;Reckamp, K.L.;Kim, Y.-C.;Novello, S.;Smit, E.F.;Lee, J.-S.;Su, W.-C.;Akerley, W.L.;Blakely, C.M.;Groen, H.J.M.;Bazhenova, L.;Carcereny, Costa E.;Chiari, R.;Hsia, T.-C.;Golsorkhi, T.;Despain, Despain D.;Shih, D.;Popat, S.;Wakelee, H. |
| 國立成功大學 |
2021 |
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study
|
Hsu, J.C.;Nguyen, P.-A.;Chen, Y.-T.;Yang, S.-C.;Lin, C.-C.;Yang, Yang Y.-H.;Lin, Y.-C.;Hsia, T.-C.;Hsieh, Hsieh H.-C.;Wu, J.-S.;Chang, Chang C.-P.;Feng, Y.-H.;Lin, P.-C.;Hsu, P.-C.;Tzeng, H.-E.;Chien, S.-C.;Chang, W.-C.;Chang, Chang C.-C.;Yang, H.-C.;Lee, C.M.;Lu, C.Y. |
| 臺大學術典藏 |
2020-12-02T02:34:00Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A. |
| 臺大學術典藏 |
2020-12-02T02:33:31Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Pan-Chyr Yang; Chang G.-C.; Hsu K.-H.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:29Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Pan-Chyr Yang; Yang T.-Y.; Chang G.-C.; Tseng C.-H.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:33:20Z |
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
|
Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; Yu S.-L.; Su K.-Y.; Yu C.-J.; Ho C.C.; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Pan-Chyr Yang; Chen J.J.W.; Chang G.-C.; Hsu K.-H.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-09-23T06:22:49Z |
Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer
|
Hsia T.C.;Shen Y.Y.;Ruoh-Fang Yen;Kao C.H.;Changlai S.P.; Hsia T.C.; Shen Y.Y.; RUOH-FANG YEN; Kao C.H.; Changlai S.P. |
| 臺大學術典藏 |
2020-08-13T06:33:49Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L. |
| 臺大學術典藏 |
2020-08-13T06:33:43Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Yang T.-Y.; Chiu K.-L.; Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chang G.-C.; Yang P.-C.; Yu C.-J.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; JIN-YUAN SHIH; Yu S.-L. |
| 臺大學術典藏 |
2020-08-13T06:33:42Z |
Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations
|
Chuang C.-Y.; Yu-Wung Yeh D.; Lin C.-B.; Hsiao S.-H.; Lin Y.-C.; Ho C.-L.; Hsia T.-C.; Wu M.-F.; Lai C.-L.; Lee K.-Y.; Wang C.-C.; Chiu C.-H.; Yang C.-T.; JIN-YUAN SHIH; Huang M.-S.; Su W.-C.; Lai R.-S.; Chang F.-K.; Tsai C.-M.; Perng R.-P.; Chih-Hsin Yang J. |
| 臺大學術典藏 |
2020-08-12T06:35:26Z |
Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study
|
Fan W.-C.;Chong-Jen Yu;Tsai C.-M.;Huang M.-S.;Lai C.-L.;Hsia T.-C.;Tien Y.-J.;Huang S.-F.;Wu C.-H.;Chou K.-T.;Lee Y.-C.;Perng R.-P.;Chen Y.-M.; Fan W.-C.; CHONG-JEN YU; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. |
| 臺大學術典藏 |
2020-08-12T06:34:14Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.;Chih-Hsin Yang J.;Su W.-C.;Chong I.-W.;Hsia T.-C.;Lin M.-C.;Chang G.-C.;Chiu C.-H.;Ho C.-C.;Wu S.-Y.;Hung J.-Y.;Wang C.-C.;Yang T.-Y.;Chong-Jen Yu; Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.;Chih-Hsin Yang J.;Su W.-C.;Chong I.-W.;Hsia T.-C.;Lin M.-C.;Chang G.-C.;Chiu C.-H.;Chao-Chi Ho;Wu S.-Y.;Hung J.-Y.;Wang C.-C.;Yang T.-Y.;Yu C.-J.; Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:27Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.; CHAO-CHI HO; Hsia T.-C.; Tseng J.-S.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:26Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:24Z |
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
|
Chen J.J.W.; Chang G.-C.; Yang P.-C.; Liu C.-M.; Chiu K.-L.; Wu M.-F.; Hsia T.-C.; CHAO-CHI HO; Yu C.-J.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; Yu S.-L.; Su K.-Y.; Yang T.-Y.; Wang C.-L.; Hsu K.-H.; Tseng J.-S. |
